021-51111890
购物车（）
sales@molnova.cn
Fungal Infection
Blocking undesired inflammatory effects also has the potential to disrupt the body’s immune response and increase the risk for infections, including fungal infections.Significant advances have been made in the development of biologic therapies targeting proinflammatory mediators to treat immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis,
psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Tumor necrosis factor-alpha (TNF-α) inhibitors were among the first biologics developed with infliximab and etanercept, gaining FDA approval in 1998. Since then, three other TNF-α inhibitors and several more biologic therapies that target other proinflammatory mediators, including interleukin (IL)-1, IL-6, IL-12, IL-23, and janus kinase (JAK) have been approved for use, and many more are under development. These biologic therapies have two things in common: they block the undesired inflammatory effects of a dysregulated immune system, but they also have the potential to disrupt the body’s immune response that would normally be mounted against pathogens.
References
1.Georgios Chamilos,et al. AUTOPHAGY 2016, VOL. 12, NO. 5, 888–889.
2.Carmona EM, et al. Clin Chest Med. 2017;38(3):393–402.
psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Tumor necrosis factor-alpha (TNF-α) inhibitors were among the first biologics developed with infliximab and etanercept, gaining FDA approval in 1998. Since then, three other TNF-α inhibitors and several more biologic therapies that target other proinflammatory mediators, including interleukin (IL)-1, IL-6, IL-12, IL-23, and janus kinase (JAK) have been approved for use, and many more are under development. These biologic therapies have two things in common: they block the undesired inflammatory effects of a dysregulated immune system, but they also have the potential to disrupt the body’s immune response that would normally be mounted against pathogens.
References
1.Georgios Chamilos,et al. AUTOPHAGY 2016, VOL. 12, NO. 5, 888–889.
2.Carmona EM, et al. Clin Chest Med. 2017;38(3):393–402.
